Official Journal of Research Center for Gastroenterology and Liver Diseases
Authors
During antiviral therapy for chronic hepatitis B, renal function impairment could be a critical concern when oral nucleot(s)ide analogues were used. Paradoxically, long-term telbivudine treatment was associated with an increase of estimated glomerular filtration rate (eGFR) through unknown mechanisms.
We aimed to investigate changes in serum protein abundances associated with renal function in response to antiviral treatments.
Primarily, a transcriptomic assay was performed to identify differentially expressed genes in peripheral blood cells caused by the telbivudine treatment. Two genes coding angiotensin converting enzyme (ACE) and complement factor H (CFH) were screened from 14 candidate renal function-related genes. ACE and CFH production were further investigated using enzyme-linked immunoassays.
Verification studies showed no significant change of serum CFH levels, but there was a significant reduction of serum ACE levels by continuous telbivudine treatment for 330.00 0.85 days (34 patients; paired t-test, P = 0.022). Serum HBV DNA and ALT levels also decreased (P = 0.008 and < 0.001, respectively). A significant increase in eGFR was found (33 patients, paired t-test, P = 0.002) at 708.64 31.63 days. Patients eGFRs were negatively correlated with serum ACE levels (r = -0.375, P = 0.002) but not with serum HBV DNA and ALT levels (P = 0.241 and 0.088 respectively). Significant decreases of the ACE levels were also observed upon entecavir treatment (20 patients; paired t-test, P = 0.020) at 412.88 36.92 days. No significant correlation was found between serum ACE levels and eGFRs (r = -0.239, P = 0.138) in entecavir-treated patients.
We discovered a consistent reduction of serum ACE levels by two oral antiviral monotherapies, entecavir and telbivudine. Serum ACE levels were negatively correlated with eGFRs in telbivudine treated patients.
© 2013, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Jiang L, Hu S, He M, Tian D. Estimated Glomerular Filtration Rate Increases in Chronic Hepatitis B Patients Treated With Telbivudine Monotherapy and Combination Treatment. Hepat Mon. 2016;16(1):e32528. doi: https://doi.org/10.5812/hepatmon.32528
Zhu X, Lu L, Wang Y, Xu K, Li D, et al. Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B. Hepat Mon. 2011;11(12):e93029. doi: https://doi.org/10.5812/kowsar.1735143X.795
Pradat P, Virlogeux V, Maynard M, Leclercq M, Hatu G, et al. Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy. Hepat Mon. 2015;15(9):e28879. doi: https://doi.org/10.5812/hepatmon.28879
Gong X, Chen Z, Zhang X, Zheng Y, Zhang H. Effects of Entecavir on Serum Hepatitis B Virus-DNA, Interferon-γ, and Pregenomic RNA in Patients with Chronic Hepatitis B Virus Infection. Hepat Mon. 2023;23(1):e132684. doi: https://doi.org/10.5812/hepatmon-132684
Gluhovschi C, Velciov S, Buzas R, Petrica L, Bozdog G, et al. Is There any Difference Between the Glomerular Filtration Rate of Patients With Chronic Hepatitis B and C and Patients With Cirrhosis?. Hepat Mon. 2013;13(4):e6789. doi: https://doi.org/10.5812/hepatmon.6789
Last Update: 1 week ago
Last Update: 1 week ago
Last Update: 1 week ago
Last Update: 1 hour ago
Last Update: 7 hours ago
Last Update: 5 days ago
